Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease

Four-year treatment slows cognitive decline with consistent safety profile

Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the Alzheimer’s Association International Conference 2025, held in Toronto and virtually.

Results from the Clarity AD open label extension show that lecanemab slowed clinical decline by 1.75 points on the Clinical Dementia Rating-Sum of Boxes scale, compared to expected decline in the ADNI cohort. This effect was observed across…